Efficacy and safety of fixed-dose oral Sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease

European Urology

Volumn 41, Issue 4, 2002, Pages 382-386

  Raffaele, R ^a   Vecchio, I ^a   Giammusso, B ^a   Morgia, G ^a   Brunetto, M B ^a   Rampello, L ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Depression; Erectile dysfunction; Parkinson's disease; Sildenafil

Indexed keywords

SILDENAFIL;

ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; ERECTILE DYSFUNCTION; FLUSHING; HAMILTON SCALE; HEADACHE; HUMAN; MALE; ORGASM; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATIENT SATISFACTION; PENIS ERECTION; PRIORITY JOURNAL; SIDE EFFECT;

ADMINISTRATION, ORAL; DEPRESSION; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; PARKINSON DISEASE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PROSPECTIVE STUDIES;

EID: 0036555366     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(02)00054-4     Document Type: Article

References (32)

1. Parkinson J. An Essay on the Shaking Palsy. London: Sherwood, Neely and Jones, 1817.
2. Goetz CG. Charcot on Parkinson's disease. Mov Disord 1986;I:27-32.
3. Adams RD, Victor M, Ropper AH. Principles of Neurology. New York: McGraw-Hill, 1998.
4. Stocchi F, Brusa L. Cognition and emotion in different stages and subtypes of Parkinson's disease. J Neurol 2000;247(Suppl 2).
5. Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson's disease. Mov Disord 1997;12:756-9.
6. Gotham AM, Brown RG, Marsden CD. Depression in Parkinson's disease: A quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 1986;49:381-9.
7. Cummings JL. Depression and Parkinson's disease: A review. Am J Psychiatry 1992;149:443-54.
8. NIH Consensus Conference, NIH consensus development panel on impotence. Impotence JAMA 1993;270:83-90.
9. Shah PK. Sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998:339-699.
10. Goldenberg MM. Safety and efficacy of Sildenafil citrate in the treatment of male erectile dysfunction. Clin Ther 1998;20:1033-48.
11. Saldana MJ, Villaran C, Alhalel B. Sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;339:701-2.
12. Goldstein J, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wiecker PA. Oral Sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;338:1397-404.
13. Booleil M, Gepi Attee S, Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Brit J Urol 1996;78:257-61.
14. Marks LS, Duda C, Dorey FJ, Macairan ML, Santos PB. Treatment of erectile dysfunction with Sildenafil. Urology 1999;53:19-24.
15. Fahn S, Elton RL., member of the UPDRS development committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, et al., editors. Recent Developments in Parkinson's Disease, Vol. 2. Florham Park, NJ: Mc-Millan Healthcare Information, 1987. p. 153-63.
16. Beck AT, Ward C, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-7.
17. Beck AT, Beamesderfer A. Assessment of depression the depression inventory. In: Pichot P, editor. Psychological Measurements in Psychopharmacology, Vol. 7. Paris: Kargel-Basel, 1974.
18. Hamilton M. The assessment of anxiety state by rating. Brit J Med Psychol 1959;32:50-5.
19. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-60.
20. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): A multi-dimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-30.
21. Brown RG, Jahanshahi M, Quinn N, Marsden CD. Sexual function in patients with Parkinson's disease and their partners. J Neurol Neurosurg Psychiatry 1990;53:480-6.
22. Cleeves L, Findley LJ. Bromocriptine induced impotence in Parkinson's disease. BMJ 1987;295:367-8.
23. Helfried, J, Vieregge A, Vieregge P. Sexuality in young patients with Parkinson's disease: A population based comparison with healthy controls. J Neurol Neurosurg Psychiatry 2000;69:550-2.
24. Longstreth Jr WR, Linde M. Sickness: Impact profile in Parkinson's disease. Neurology 1984;34(Suppl 1):207-8.
25. Lipe H, Longstreth WT, Bird RD, Linde M. Sexual function in married men with Parkinson's disease compared to married men with arthritis. Neurology 1990;40:1347-9.
26. Commings JL. Psychosomatic aspects of movement disorders. Adv Psychosom Med 1985;13:111-32.
27. Mayeux R. Parkinson's disease. J Clin Psychiatry 1990;51:20-3.
28. Randrup A, Munkvad I, Fog R, et al. Mania, depression, and brain dopamine. In: Essman WB, Valzelli L, editors. Current Development in Psychopharmacology. New York: Spectrum Publications, 1975. p. 207-29.
29. Goodwin FK, Sack RL. Central dopamine function in affective illness: Evidence from precursors, enzyme inhibitors, and studies of central dopamine turnover. In: Usdin E, editor. Neuropsychopharmacology of Monoamines and their Regulatory Enzymes. New York: Raven, 1974. p. 261-77.
30. McKinney WT, Kane FJ. Depression with the use of alpha-methyldopa. Am J Psychiatry 1967;124:118-9.
31. Willner P. Dopamine and depression: A review of recent evidence. Part II. Theoretical approaches. Brain Res 1983;287(3):225-36.
32. Koob GE. Drug addiction: The yin and yang of hedonic homeostasis. Neuron 1996;16:893-6.